JPMorgan Lowers GSK Price Target, Maintains Underweight Rating

Core Viewpoint - GSK plc is recognized as one of the best European dividend stocks to consider for investment, despite a recent price target reduction by JPMorgan [1][2]. Financial Performance - GSK shares have appreciated nearly 40% since the beginning of 2025, attributed to strong third-quarter results and an optimistic outlook for 2025 [3]. - The company reported sales of £8.5 billion, reflecting a year-on-year increase of approximately 7%, with the Specialty Medicines division achieving a notable growth of 16% to £3.4 billion [3]. Product Performance - Oncology sales surged nearly 39%, showcasing the effectiveness of GSK's new drug portfolio following the divestment of its pharmaceutical arm [4]. - Positive clinical updates, particularly for respiratory biologics and the RSV vaccine, have further bolstered the company's performance [4]. Analyst Ratings - JPMorgan has lowered its price target for GSK to 1,440 GBp from 1,550 GBp while maintaining an Underweight rating on the stock [2].